InDex Pharmaceuticals Entered into a License Agreement with Viatris to Develop and Commercialize Cobitolimod for Ulcerative Colitis in Japan
Shots:
- InDex will receive $10M up front for the exclusive rights to commercialize cobitolimod in Japan & is eligible to receive development and sales milestones of ~$40M along with royalties based on its net sales for the product in Japan
- InDex will be in charge of continuing to fund all development incorporating the completion of the P-III program (CONCLUDE) incl. a cohort of Japanese patients in (Induction Study 2) and a PK study before filing. Viatris will be responsible to fund all regulatory and commercialization expenses, as well as any additional Japanese-specific studies required in Japan
- Cobitolimod, a TLR9 agonist is being evaluated in the P-III program (CONCLUDE) for mod. to sev. UC
Ref: PRNewswire | Image: Viatris
Related News:- Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
